logo
#

Latest news with #QIAGENN.V

Europe Digital PCR Industry Research Report 2025: Increased Use of Digital-PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plans
Europe Digital PCR Industry Research Report 2025: Increased Use of Digital-PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plans

Yahoo

time26-05-2025

  • Business
  • Yahoo

Europe Digital PCR Industry Research Report 2025: Increased Use of Digital-PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plans

The market for digital PCR is growing quickly in Europe due to the growing use of personalised medicine and the need for extremely accurate diagnostics. With its remarkable sensitivity and specificity, digital PCR (dPCR) is especially useful for identifying low-abundance genetic mutations and measuring biomarkers that are essential for early diagnosis and treatment monitoring. Increasing rates of infectious diseases, genetic disorders, and cancers have prompted investments in cutting-edge molecular diagnostic technologies. European Digital PCR Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Europe Digital PCR Market: Focus on Application, End User, and Country Analysis - Analysis and Forecast, 2024-2034" report has been added to Europe digital PCR (d-PCR) market is projected to reach $762.7 million by 2034 from $183.9 million in 2024, growing at a CAGR of 15.29% during the forecast period 2024-2034 The European digital PCR market is expected to grow steadily as top research institutes and business leaders keep working together to create reliable, patient-specific diagnostic solutions. In addition to changing the molecular diagnostics landscape, this dynamic market is opening the door for individualised treatment plans that improve patient outcomes. The accuracy, throughput, and ease of integration of assays into clinical workflows have been greatly enhanced by technological advancements like droplet digital PCR, nanoplate technology, and microfluidic platforms. Furthermore, market adoption has accelerated throughout the continent due to government initiatives, favourable regulatory frameworks, and increased funding for healthcare infrastructure. Overall, the convergence of technological innovation, regulatory support, and evolving clinical demands is driving the digital PCR market's robust expansion in Europe. Additionally, growing research collaborations and investments will further integrate digital PCR in Europe. How can this report add value to an organization? Product/Innovation Strategy: The Europe digital PCR market has been extensively segmented based on various categories, such as application, end user, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming Strategy: Mergers, acquisitions, and product launches accounted for the maximum number of key Strategy: The Europe digital PCR market has numerous established players with product portfolios. Key players in the Europe digital PCR market analyzed and profiled in the study involve established players offering products for digital Market Players QIAGEN N.V. F. Hoffmann-La Roche Ltd Merck KGaA Stilla Technologies Inc. SAGA Diagnostics AB JETA Molecular BV. Key Attributes: Report Attribute Details No. of Pages 72 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $183.9 Million Forecasted Market Value (USD) by 2034 $762.7 Million Compound Annual Growth Rate 15.2% Regions Covered Europe Key Topics Covered: Executive SummaryScope and Definition1 Markets1.1 Market Overview1.1.1 Workflow of Digital PCR1.1.2 Comparison of qPCR and dPCR1.2 Trends: Current and Future Impact Assessment1.2.1 Integration with Next-Generation Sequencing (NGS)1.2.2 Increased Real-time Monitoring and Point-of-care Applications of Digital PCR1.2.3 Increasing Product Launches in d-PCR Ecosystem1.3 Supply Chain Overview1.4 Research and Development Review1.4.1 Patent Filing Trend (by Region)1.4.2 Patent Filing Trend (by Country)1.4.3 Patent Filing Trend (by Year)1.5 Ongoing Digital PCR Clinical Trials1.6 Regulatory Landscape1.6.1 European Union1.7 Market Dynamics Overview1.7.1 Market Drivers1.7.1.1 Increasing Adoption of Personalized Medicine for Screening and Diagnostics of Genetic Disorders such as Rare Diseases and Cancer1.7.1.2 Increasing Incidence of Infectious Diseases1.7.1.3 Technological Advancement in dPCR to Enhance Market Growth1.7.2 Market Restraints1.7.2.1 High Cost of Platforms Associated with Digital-PCR1.7.2.2 Shortage of Skilled Professionals and Trained Laboratory Technicians1.7.3 Market Opportunities1.7.3.1 Increased Use of Digital-PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan1.7.3.2 Growing Adoption of dPCR in Emerging Markets2 Regions2.1 Regional Summary2.2 Drivers and Restraints2.3 Europe2.3.1 Regional Overview2.3.2 Driving Factors for Market Growth2.3.3 Factors Challenging the Market2.3.4 By Application2.3.5 By End User2.3.6 France2.3.7 Germany2.3.8 U.K.2.3.9 Spain2.3.10 Italy2.3.11 Rest-of-Europe3 Markets - Competitive Benchmarking & Company Profiles3.1 Competitive Landscape3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Product Launch and Approval Activities3.1.4 Expansion, Funding, and Other Activities3.2 Market Share Analysis3.3 Company Profile3.3.1 Overview3.3.2 Top Products/Product Portfolio3.3.3 Top Competitors3.3.4 Target Customers3.3.5 Key Personnel3.3.6 Analyst View4 Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Digital PCR Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast
QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

Associated Press

time08-04-2025

  • Business
  • Associated Press

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

VENLO, The Netherlands--(BUSINESS WIRE)--Apr 8, 2025-- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, May 8, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. Three options for joining theconference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 U.S.: +1 646 828 8193 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 5803222 To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. Further information can be found at category: Financial Vice President Head of Corporate Communications +49 2103 29 11711 +49 152 018 11711 +1 240 686 2222 Email: [email protected] Domenica Martorana Associate Director Investor Relations +49 2103 29 11244 +49 152 018 11244 KEYWORD: NETHERLANDS EUROPE SOURCE: QIAGEN N.V. Copyright Business Wire 2025. PUB: 04/08/2025 11:22 AM/DISC: 04/08/2025 11:22 AM

QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook
QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook

Associated Press

time07-04-2025

  • Business
  • Associated Press

QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook

Ad hoc Announcement according to Art. 17 Market Abuse Regulation QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook VENLO, THE NETHERLANDS / ACCESS Newswire / April 6, 2025 / QIAGEN N.V. (NYSE:QGEN)(Frankfurt Prime Standard:QIA) announces preliminary Q1 2025 results that exceed the outlook for both net sales and adjusted earnings per share (EPS), and also updates its adjusted EPS outlook for full-year 2025, reflecting strong performances across many growth drivers. Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, surpassing the previously communicated outlook for about 3% CER growth (4% CER core business excluding discontinued products such as NeuMoDx and Dialunox). Adjusted diluted EPS are expected to be at least $0.55 CER compared to the previously communicated outlook for about $0.50 CER. Sales of the QuantiFERON latent TB test grew about 15% CER as global adoption continues to shift from the skin test to this proven, modern blood-based test. The QIAstat-Dx syndromic testing system advanced above 35% CER on continued demand for respiratory panels along with growth in gastrointestinal and meningitis testing. The QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business both delivered high-single-digit CER gains, reflecting solid adoption across research and clinical applications. Additional growth contributions also came from higher sales of PCR consumables and from OEM products. Sample technologies sales declined 1% CER, reflecting the cautious instrument spending environment among some Life Sciences customers. Given the positive start to 2025, QIAGEN is raising its adjusted diluted EPS outlook for full-year 2025 in light of the strong sales growth in Q1 and the overall current business trends, which includes expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment. Full-year 2025, adjusted diluted EPS are now expected to be about $2.35 CER, up from the prior full-year outlook for about $2.28 CER, while reaffirming the goal to improve the adjusted operating income margin to above 30% for the year. QIAGEN N.V. Hulsterweg 82 5912 PL Venlo The Netherlands Frankfurt Stock Exchange, Regulated Market (Prime Standard) End of Inside Information

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook
QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

Yahoo

time06-04-2025

  • Business
  • Yahoo

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER) On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target VENLO, Netherlands, April 06, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting strong performances across many growth drivers. Net sales grew approximately 5% (+7% at constant exchange rates, CER) to about $483 million in Q1 2025, surpassing the previously communicated outlook for about 3% CER growth (4% CER core business excluding discontinued products such as NeuMoDx and Dialunox). Adjusted diluted EPS are expected to be at least $0.55 CER compared to the previously communicated outlook for about $0.50 CER. Sales of the QuantiFERON latent TB test grew about 15% CER as global adoption continues to shift from the skin test to this proven, modern blood-based test. The QIAstat-Dx syndromic testing system advanced above 35% CER on continued demand for respiratory panels along with growth in gastrointestinal and meningitis testing. The QIAcuity digital PCR system and QIAGEN Digital Insights bioinformatics business both delivered high-single-digit CER gains, reflecting solid adoption across research and clinical applications. Additional growth contributions also came from higher sales of PCR consumables and from OEM products. Sample technologies sales declined 1% CER, reflecting the cautious instrument spending environment among some Life Sciences customers. Given the positive start to 2025, QIAGEN is raising its adjusted diluted EPS outlook for full-year 2025 in light of the strong sales growth in Q1 and the overall current business trends, which includes expected headwinds from the recently announced U.S. import tariffs and a better-than-expected tax environment. Full-year 2025, adjusted diluted EPS are now expected to be about $2.35 CER, up from the prior full-year outlook for about $2.28 CER, while reaffirming the goal to improve the adjusted operating income margin to above 30% for the year. QIAGEN will provide additional perspectives on the outlook for full-year 2025 with the publication of full Q1 2025 results on May 7, 2025. Additionally, QIAGEN now expects to reach the mid-term adjusted operating income margin goal of at least 31% well ahead of the original 2028 timeline, reflecting the stronger-than-anticipated improvements delivered during 2024 and 2025. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit Forward-Looking StatementCertain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's financial and operational outlook, including its expected Q1 25 and full year net sales, adjusted diluted EPS and adjusted operating income margin, products, development timelines, marketing and / or regulatory approvals, growth strategies, collaborations and operating results are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, tariffs, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated financial and operational results will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Source: QIAGENCategory: Corporate View source version on Contacts Contacts QIAGEN: Investor Relations John Gilardi, +49 2103 29 11711Domenica Martorana, +49 2103 29 11244e-mail: ir@ Public Relations Thomas Theuringer, +49 2103 29 11826e-mail: pr@

QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts
QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

Yahoo

time01-04-2025

  • Health
  • Yahoo

QIAGEN Launches QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

Malaria remains a major global health threat, with more than 250 million cases and 600,000 deaths in 2024 – over 90% of them in Africa QIAprep& Plasmodium Kit enables streamlined detection of five malaria-causing parasites for epidemiological research and surveillance Novel QIAGEN assays support mixed-infection tracking, vaccine impact assessment and malaria control strategies in regions with limited healthcare infrastructure VENLO, Netherlands, April 01, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep& Plasmodium Kit and two companion assays to support malaria research and surveillance efforts. This new solution combines sample preparation and quantitative PCR (qPCR) into a single workflow, providing a rapid and accessible tool for detecting malaria-causing parasites from blood samples. Malaria remains one of the world's most pressing public health challenges, particularly in tropical and subtropical regions. The disease is caused by five species of Plasmodium parasites, with Plasmodium falciparum responsible for the most severe cases. In 2024 alone, malaria accounted for more than 250 million cases worldwide, with over 90% occurring in Africa. While the integration of vaccines into anti-malaria programs began in 2024, and mark a significant milestone, comprehensive monitoring of parasite prevalence and evolution is essential for disease control. The QIAprep& Plasmodium Kit simplifies malaria research by enabling the detection of all five Plasmodium species in human samples. "Malaria research and surveillance remains critical in the fight against this potentially fatal disease, especially as control efforts evolve," said Swathi Kumar, Head of Global PCR, Enzymes & Oligos at QIAGEN. "Our new QIAprep& Plasmodium Kit and assays allow researchers to monitor disease prevalence through high-frequency screening so they can better track the spread of this disease, study vaccine effectiveness and identify emerging dominant parasite strains that may impact treatment and containment strategies." QIAGEN's QIAprep& technology – originally developed for COVID-19 research – integrates liquid-based sample preparation with qPCR into a streamlined and cost-efficient workflow. It offers high sensitivity, detecting as little as one parasite per microliter, and is compatible with both liquid and dried blood samples, including QIAcard FTA cards. It is also suitable for use on many qPCR platforms, including QIAGEN's Rotor-Gene Q. The accompanying assays further enhance malaria research detection and differentiation. The QIAGEN Pf/Non-Pf Detection Assay is a single-reaction screen for the most common cause of malaria in humans involving Plasmodium falciparum, while the QIAGEN Pv/Pm/Po/Pk Detection Assay helps distinguish between the remaining four common species that cause malaria – P. vivax, P. malariae, P. ovale, and P. knowlesi – allowing scientists to track mixed infections, study parasite evolution during vaccine rollouts and ensure that comprehensive epidemiological surveillance data is available when designing response measures. For more information about the QIAprep& Plasmodium Kit and assays, visit: About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue, and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Source: QIAGEN N.V. Category: Corporate View source version on Contacts Contacts QIAGEN:Investor RelationsJohn Gilardi +49 2103 29 11711Domenica Martorana +49 2103 29 11244e-mail: ir@ Public Relations Thomas Theuringer +49 2103 29 11826Lisa Specht +49 2103 29 14181e-mail: pr@ Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store